The 2005 National Institutes of Health (NIH) consensus criteria for chronic GVHD have set standards for reporting. Many questions, however, have arisen regarding their implementation and utilization. To identify perceived areas of controversy, we conducted an international survey on diagnosis and scoring of chronic GVHD. Agreement was observed for 50-83% of the 72 questions in 7 topic areas. There was agreement on the need for modifying criteria in six situations: two or more distinctive manifestations should be enough to diagnose chronic GVHD; symptoms that are not due to chronic GVHD should be scored differently; active disease and fixed deficits should be distinguished; a minimum threshold body surface area of hidebound skin involvement should be required for a skin score of 3; asymptomatic oral lichenoid changes should be considered a score 1; and lung biopsy should be unnecessary to diagnose chronic GVHD in a patient with bronchiolitis obliterans as the only manifestation. The survey also identified 26 points of controversy. Whenever possible, studies should be conducted to confirm the appropriateness of any revisions. In cases where data are not available, clarification of the NIH recommendations by consensus is necessary. This survey should inform future research in the field and revisions of the current consensus criteria.
INTRODUCTION
Chronic GVHD is an immune-mediated disorder that occurs in 30-50% of patients after allogeneic hematopoietic cell transplantation (HCT). [1] [2] [3] Chronic GVHD causes significant late morbidity and mortality and affects the quality of life, survival and other transplant outcomes. In 2005, the National Institutes of Health (NIH) convened an expert conference to develop consensus on criteria for diagnosis, staging, pathology, biomarkers, response measurement, supportive care and design of clinical trials. [4] [5] [6] [7] [8] [9] The major goal of the consensus project was to develop a 'standardized common language' among investigators focused on chronic GVHD in order to facilitate comparisons between clinical studies. Although many studies have reported the validity of the Consensus criteria, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] implementation of the criteria in daily work has raised many practical questions. 28, 29 Participants in the conference anticipated that the advent of new data and experience applying the criteria to actual clinical situations may necessitate clarifications, corrections, refinement and perhaps revisions of the criteria.
The goals of this survey were to identify areas of confusion or disagreement with the NIH criteria, particularly for diagnosis and severity scoring of chronic GVHD. We generated a questionnaire based on queries collected from various sources and conducted a detailed survey among a voluntary group of international investigators who are interested in chronic GVHD research. The results of this survey should help determine the next steps for research activities aiming to refine or modify the consensus criteria for chronic GVHD.
MATERIALS AND METHODS Survey
Since the 2005 NIH consensus conference, the authors have collected frequently asked questions (FAQs) about the NIH consensus recommendations from various sources. Most FAQs came from health-care professionals throughout the world, and some arose in the context of clinical trials. Two of the authors (YI and SJL) reviewed all collected FAQs and summarized them into 72 questions (Supplementary Appendix). Questions were formatted to elicit opinions about best practices for the future rather than asking how respondents were applying the current NIH recommendations. Two other authors (MJ and SP) critically reviewed the draft question list and undertook the survey to establish the anticipated completion time before the questionnaire was finalized. An invitation to complete the survey was sent to 64 members of the International Chronic GVHD Special Interest Group in February 2013, with two e-mail reminders sent 2 weeks and 3 weeks after the survey invitation. The International Chronic GVHD Special Interest Group is a voluntary group of investigators who are interested in chronic GVHD research. The group is organized by one of the authors (SJL) and anyone can participate in the group by emailing their interest to chronicGVHDstudies@fhcrc.org. A web-based survey (Survey Monkey) was used to collect responses over a 5-week period. The invitation included information about a chance to win two $500 gift cards for respondents who completed the survey by the deadline. The study protocol was approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center.
X60% but o80% respondents chose the same answer. Agreement was considered controversial when o60% respondents chose the same answer. Three questions that had multiple components (Q10, Q14 and Q19) were reported according to the agreement level for each component.
Analyzed topic areas
Analysis was performed according to seven clinically relevant topic areas in the questionnaire (Table 1) . Fourteen questions asked specifically whether the current NIH recommendations should be revised. 
RESULTS
Survey response and characteristics of participants A total of 48 (75%) of 64 invited investigators completed the survey within 5 weeks after the survey commenced. Six (13%) respondents had 3-5 years of experience in caring for patients with chronic GVHD, 14 (29%) had 6-10 years, 15 (31%) had 11-20 years and 11 (23%) had more than 20 years of experience. Forty-four (92%) respondents were physicians and 40 (83%) considered themselves experts in the management of chronic GVHD. Respondents were from North America (67%), Europe (15%), South America (10%), Asia (6%) and the Middle East (2%).
The raw results of the survey are provided in Supplementary Appendix.
Agreement in answers according to topic areas At least moderate agreement was observed for 50-83% of questions according to topic areas ( Figure 1) . A high degree of agreement was most frequently observed in responses to questions about the method of scoring symptoms not due to GVHD, where respondents clearly favored distinguishing symptoms based on whether they were attributable to chronic GVHD. Controversies were most frequently observed in responses to questions prompted by a lack of clarity in the current NIH consensus, where respondents seemed to apply their own interpretations to the presented scenarios. Detailed results according to topic areas are shown in Table 1 .
Opinions regarding revision of the current NIH recommendations Among the 14 questions that asked whether the current NIH recommendations should be revised ( Many issues related to diagnostic and distinctive manifestations were controversial: for example, whether there were any diagnostic features for the eyes, liver and GI tract other than the esophagus; whether classification of late acute GVHD and overlap chronic GVHD should be determined only by the current condition or by the history of chronic GVHD; whether gingivitis, oral mucositis and pain should remain as common signs; and whether joint pain mimicking rheumatoid arthritis is a manifestation of GVHD. Controversy also arose in the question of whether cryptogenic organizing pneumonia should remain a common sign of GVHD, should be a distinctive sign of chronic GVHD, or should be removed as a manifestation of GVHD.
Topic 2: Can pathology discriminate chronic GVHD from other causes? Respondents agreed that pathology could distinguish chronic GVHD from acute GVHD or other etiologies in the skin, lung, mouth and muscle but not in the liver and GI tract other than the esophagus. Usefulness of pathology in distinguishing chronic GVHD in the fascia, esophagus and genital tract was controversial. We did not ask whether pathology could distinguish different infections.
Topic 3: Is biopsy necessary to diagnose chronic GVHD in certain organs? Respondents agreed that biopsy was not always necessary to confirm chronic GVHD in the skin, liver and GI tract if the patient had diagnostic chronic GVHD in other sites. Respondents agreed that diarrhea should be scored as chronic GVHD even for negative biopsy results in patients with chronic GVHD. It was controversial whether gastrointestinal biopsy was necessary to confirm GVHD in patients with upper GI symptoms.
Topic 4: Should criteria for severity scoring of chronic GVHD be revised? Respondents agreed that fixed deficits and active chronic GVHD should be distinguished when manifestations are scored, but there was controversy on whether revisions should be made for both severity scoring and response measurement or only for response measurement. The current consensus does not clearly specify whether manifestations other than the eight core sites (skin, mouth, eyes, lung, liver, GI tract, joints and fascia and genital tract) should be included in the global scoring system. Respondents agreed that esophageal stricture, thrombocytopenia and pericardial or pleural effusion but not cardiac complications should be included, although they remain difficult to score. Inclusion of performance status and other manifestations was controversial. For the skin, respondents agreed that maculopapular rash, lichenoid features, erythroderma, sclerosis, erythema, papulosquamous lesions or ichthyosis, poikiloderma, keratosis pilaris and hair involvement should all be considered when determining the skin score, whereas controversy arose in the question of whether hypo-or hyperpigmentation, pruritus and nail involvement should be considered when determining the skin score as currently recommended. Respondents agreed that hidebound changes should not be rated as skin score 3 if the body surface area affected was minimal, and that mouth score 1 should be revised so that it includes asymptomatic lichenoid changes that are currently scored as 0. Respondents reaffirmed the current NIH recommendations that mechanical interventions for dry eye, such as punctual plugging and corneal lenses, and visual impairment should be considered in the eye severity score. The use of a dilator for vaginal stricture in the absence of symptoms as an indicator of severe involvement was controversial.
Topic 5: Should manifestations not due to GVHD be included in the scoring? Overall, respondents agreed that symptoms clearly attributable to causes other than GVHD should not be scored. For example, respondents agreed that eye, joint or fascia, and lung manifestations should not be scored if they predated transplantation and were stable. In cases where clinicians were not sure of the etiology, respondents agreed that symptoms should be included in the chronic GVHD scoring. It was controversial whether the score should be downgraded by a single point from the actual score when other proven etiologies were present.
Topic 6: How should discrepancies between different evaluations be handled? For the skin, eyes, lung and genital tract, respondents agreed with the use of the worst manifestation when the patient had discrepant findings in different areas rather than using the lower or average score. For the lung, respondents agreed that pulmonary symptoms should be scored 0 if pulmonary function tests were normal, although the current consensus recommended taking the higher symptom and pulmonary function test score. Answers for the mouth and liver were controversial.
Topic 7: When the current NIH recommendations lack clarity or are silent about particularly clinical situations, how should they be scored? Despite a lack of clear guidance in some of the consensus recommendations, agreement in opinions was observed for half of the questions. Respondents agreed that erectile dysfunction is not a GVHD manifestation, that some eye drops such as antibiotics and glaucoma medications should not be included for the eye score based on the frequency of eye drop use, and that all liver function tests including serum bilirubin, alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase should be considered in staging late acute GVHD of the liver. Controversies were related to the duration of resolution required for the 'recurrent' GVHD category, the reference time point used for calculation of weight loss as a manifestation of GI involvement and the methods used to evaluate patients when pulmonary function tests or gynecological exam results were missing.
DISCUSSION
In the past, studies on chronic GVHD have been compromised by lack of standardized diagnosis, grading and response assessment of chronic GVHD. The 2005 NIH consensus conference provided a common language and set of criteria, but clinical experience with the recommendations has exposed some areas of ambiguity that need clarification. Although agreement rates varied according to topic areas, at least moderate agreement was observed for X50% of questions addressing these areas, suggesting that consensus can be reached on these issues. For the most part, the controversial areas would not substantially change interpretation of the scoring or response criteria. However, two main areas where respondents disagreed with the current NIH recommendations (the rules for scoring symptoms not due to GVHD and lack of distinction between active disease and fixed deficits) might have a major impact on scoring depending on the number of other conditions contributing to the organ abnormalities. This question was discussed during the 2005 Consensus Conference, and it was decided that incorporating considerations of attribution or reversibility would complicate severity scoring as no reliable definitions of reversibility existed. The results of our survey show that real-world experience has led to discontent with the inability to include these considerations when scoring severity. Future studies should focus on clarifying these areas as they are critical to both severity scoring and response measurement. To account for manifestations not due to GVHD, scores may be downgraded in a manner similar to the modified scoring for acute GVHD. 30 As such an adjustment for concomitant diseases might result in increased heterogeneity in severity grading, this approach requires validation. To account for the distinction between activity and fixed deficits, an activity score for chronic GVHD could be developed, similar to the Systemic Lupus Erythematosus Disease Activity Index 31 or Crohn's Disease Activity Index. 32 Identification and validation of biomarkers to distinguish active and inactive chronic GVHD would be very useful as these situations may be indistinguishable by physical exam.
Other issues on which respondents disagreed with current NIH recommendations are the need for lung biopsy to diagnose bronchiolitis obliterans in the absence of other manifestations of chronic GVHD. Many clinicians recognize the risk and difficulty of lung biopsy for diagnosis of bronchiolitis obliterans and are not willing to subject patients to such risks. Similar topics were discussed at the 2009 European meeting 29 and at the 2012 BMT Tandem Meetings. 28 Another disagreement is with the rule for scoring the mouth as a 0 for asymptomatic lichenoid changes. This was based on the assumption that activities of daily living would not be affected by asymptomatic oral lichenoid changes and therefore they should be scored as a 0 in severity assessment. In addition, systemic treatment is often not indicated if oral lichenoid changes are the sole manifestation of chronic GVHD. On the other hand, if isolated lichenoid changes are not captured in organ scoring, the association of these changes with long-term sequela including secondary oral cancer would be missed. 33 Directed studies are warranted to determine the appropriateness of modifying the rule for scoring the mouth, as changes in the current mouth score correlated well with both clinician-and patient-perceived response in oral GVHD. 26 Many of the controversial issues were identified because they are common situations in clinical practice but the current NIH recommendations are unclear or lack guidance. For example, 'recurrent' late acute GVHD is defined as the development of acute GVHD beyond day 100 after prior acute GVHD has resolved, but the number of GVHD-free days required to be considered 'recurrent' versus 'persistent' has never been defined. Another example is the chronic GVHD GI severity score, which is based in part on the percentage of weight loss, although the reference time point is not specified. A routine gynecological examination for patients with chronic GVHD is required, as manifestations of genital GVHD are not always reported and are not captured unless the physical exam includes the genitalia. On the other hand, rules for scoring in the absence of gynecological examination should be given. The results of the survey also highlight the need for developing a consensus about histopathology and biomarkers of liver GVHD as clinical and laboratory findings are not diagnostic. Given the current lack of empirical data, evidence-based resolution is not possible. Efforts should be made to design appropriate studies to address those questions. Provisional consensus could be reached in other cases where need for clarifications is urgent or obvious.
This study has some limitations. First, results were derived from a relatively small group of committed investigators. Mitigating this concern is the fact that respondents are from various international regions, half have more than 10 years of experience in caring for patients with chronic GVHD, many have reported that they use the NIH criteria in clinical practice and most of the respondents have extensive experience with clinical trials in chronic GVHD. Thus, the results of this study should provide meaningful opinions. Second, we could not evaluate differences in answers according to investigators' regions or experience including years in practice and the number of patients they have seen because of limited numbers of participants.
In summary, this survey highlights areas of controversy that were not anticipated by the NIH criteria or where additional clinical experience has led investigators to question the original recommendations. These results will be useful guidance for revisiting the NIH consensus criteria, and a conference is planned in June 2014. In situations where sufficient data are available, revisions of the current recommendations will be made. In situations where additional information is needed, studies should be performed to collect these data. For other situations where data cannot be generated and recommendations are truly based on opinions, the goal should be to achieve a clear consensus to ensure standardized use of the criteria.
